A new synthetic opioid is spreading through the illicit drug supply, and the early data make sobering reading. Ella Ruder reported in Becker’s Behavioral Health on 14 September 2026 that cychlorphine has been tied to at least 55 deaths across the United States since 2025. Laboratory work suggests the drug is about 10 times more potent than fentanyl. Those facts raise a question that policy debate has been slow to confront. What happens when a response built around reversing overdoses meets a drug that is harder to detect and harder to reverse?
What the Laboratory Data Show About This New Synthetic Opioid
Cychlorphine belongs to a subclass called orphine analogues. Researchers at the Center for Forensic Science Research and Education (CFSRE) first detected it in mid 2024 and issued a public alert in January 2026. Its numbers have climbed quickly since then. The CFSRE identified the compound in 25 blood specimens from fatal overdoses, most of them submitted in late 2025 and early 2026. NMS Labs has tentatively identified it in more than 100 toxicology cases. The specimens came from eight US states and three Canadian provinces.
Another shift stands out. China placed nitazene analogues under generic control in July 2025. Since then, the alert reports, nitazene positivity has fallen while orphine positivity has risen, led largely by cychlorphine. The authors describe the timing and stop short of naming a cause.
Cychlorphine rarely travels alone. It was the only opioid in 11 of the 25 fatal cases. According to the alert’s co occurrence chart, fentanyl and its analogues appeared in eight cases, as did methamphetamine. Bromazolam and phenazolam, both novel benzodiazepines, each appeared in six. Carfentanil and nitazene analogues also turned up in some specimens.
Becker’s adds the national picture. The Knox County Regional Forensic Center in Tennessee reported 41 overdose deaths tied to the drug between July 2025 and February 2026. Ohio, Tennessee and Texas show the highest prevalence, and the drug has also appeared in Europe and on the East Coast.
Why Cychlorphine Strains the Standard Overdose Response
The Becker’s report draws on The New York Times, MedPage Today and a DEA advisory. Together they describe three practical problems.
First, naloxone may not be enough on its own. DEA guidance says cychlorphine might require several doses of naloxone to be effective, yet most people carry only one or two. Lewis Nelson, a medical toxicologist at Florida Atlantic University, told MedPage Today that naloxone must reach the patient before brain swelling occurs. Timing matters as much as quantity.
Second, standard fentanyl test strips do not detect the drug, according to the Times. Users and health systems therefore have a blind spot that fentanyl era tools were never built to cover.
Third, the barrier to making it is low. Keith Humphreys, a Stanford psychiatry professor, told the Times that the synthesis was published in academic journals decades ago and now sits online. Producers need little infrastructure.
Naloxone remains an important emergency medicine. The point here is narrower. It acts only after someone has taken the drug, only if a bystander is present, and only if enough doses are within reach.
Where Harm Reduction Alone Reaches Its Limits
Naloxone, test strips and drug checking share a design feature. Each assumes a known substance and a reversible event, and each works downstream of the supply. Cychlorphine tests both assumptions at once. The strips cannot see it, and the antidote may need repeating.
Chasing the supply with new tools also invites a long race. The CFSRE’s emergence table lists six orphine analogues, starting with brorphine in July 2020. Five of the six reached monograph stage between August 2024 and December 2025. Each new compound would need its own detection method, its own dosing guidance and its own surveillance. As a result, a response that waits for the next compound stays one step behind.
The nitazene shift points the same way. Whatever the cause, the market moved from one compound class to another within months. Prevention and supply disruption work on that upstream point, whereas reversal tools meet only its consequences.
A further concern needs careful wording. The sources reviewed here do not measure recovery outcomes, so what follows is analysis and not a finding. A framework that treats surviving the next overdose as its main measure has no built in route beyond that point. If it absorbs most of the attention and funding, prevention education and treatment access may receive less. A person revived after exposure to a drug 10 times stronger than fentanyl returns to the same supply. Reversal buys time, but recovery and prevention are what change the outcome. This argument deserves proper study.
Advocates of harm reduction answer that reversal keeps people alive long enough to reach treatment, and that the approaches complement each other. That position has force. Even so, the evidence in this alert narrows the margin it relies on. When one tool needs several doses and another cannot detect the drug, survival becomes less certain.
A Balanced Response to This New Synthetic Opioid
Early warning offers the clearest example of a layered approach. According to the Times, as cited by Becker’s, San Francisco tested wastewater for emerging substances until federal funding lapsed in 2024. The city resumed in July and plans to publish findings on novel drugs this autumn. Becker’s notes that behavioural health leaders now face questions about naloxone protocols, toxicology screening, surveillance and staff preparedness.
A layered response would likely include enough naloxone for repeat doses, wider toxicology screening and earlier detection through surveillance. It would also keep prevention and treatment in front of the people most exposed. That includes buyers of counterfeit pills, because the DEA advisory places cychlorphine in counterfeit pills as well as fentanyl supplies. Someone who believes a tablet is a prescription medicine has no way to know what it holds.
Totals remain modest. The CFSRE counts 25 confirmed fatal cases, and Becker’s cites at least 55 deaths nationally. Trend lines matter more than totals. Positive case submissions peaked in December 2025, and the tools built for fentanyl fail at the first test. A response limited to managing the overdose will keep meeting each novel synthetic opioid after the harm is done.
Sources:
Cychlorphine, explained: 10 things to know about the new synthetic opioid

Leave a Reply